The therapeutic and psychoactive properties of cannabinoids have long been recognized. The type 2 receptor for cannabinoids (CB 2 ) has emerged as an important therapeutic target in several pathologies, as it mediates beneficial effects of cannabinoids while having little if any psychotropic activity. Difficulties associated with the development of CB 2 -based therapeutic agents have been related to its intricate pharmacology, including the species specificity and functional selectivity of the CB 2 -initiated responses. We postulated that a plasmalemmal or subcellular location of the receptor may contribute to the differential signaling pathways initiated by its activation. To differentiate between these two, we used extracellular and intracellular administration of CB 2 ligands and concurrent calcium imaging in CB 2 -expressing U2OS cells. We found that extracellular administration of anandamide was ineffective, whereas 2-arachidonoyl glycerol (2-AG) and WIN55,212-2 triggered delayed, CB 2 -dependent Ca 2+ responses that were Gq protein-mediated. When microinjected, all agonists elicited fast, transient, and dose-dependent elevations in intracellular Ca 2+ concentration upon activation of Gq-coupled CB 2 receptors. The CB 2 dependency was confirmed by the sensitivity to AM630, a selective CB 2 antagonist, and by the unresponsiveness of untransfected U2OS cells to 2-AG, anandamide, or WIN55,212-2. Moreover, we provide functional and morphological evidence that CB 2 receptors are localized at the endolysosomes, while their activation releases Ca 2+ from inositol 1,4,5-trisphosphate-sensitive-and acidic-like Ca 2+ stores. Our results support the functionality of intracellular CB 2 receptors and their ability to couple to Gq and elicit Ca 2+ signaling. These findings add further complexity to CB 2 receptor pharmacology and argue for careful consideration of receptor localization in the development of CB 2 -based therapeutic agents.
A lthough cannabinoids are active at several G proteincoupled receptors and ion channels, only two "true" cannabinoid receptors are recognized, namely CB 1 and CB 2 . 1 Interest in the latter has sparked as it appeared as an important therapeutic target in inflammatory and painful conditions, 2, 3 while not being involved in the psychoactive cannabinoid effects, which are mainly CB 1 -mediated. As such, increasing effort is being spent in the development of CB 2 -based therapeutic agents. 4, 5 Nonetheless, controversies exist, for instance, in CB 2 pharmacology and distribution. 6−8 At least two CB 2 receptor isoforms have been identified, with tissueand species-specific expression patterns. 8, 9 It has been found that CB 2 agonists may elicit distinct responses at CB 2 receptors from different species. 10 Moreover, functional selectivity, defined as the ability of a receptor to couple to different signaling pathways depending on the ligand that stimulates it, 11 has been reported for CB 2 . 7 Further complexity is added to the CB 2 receptor pharmacology with the recent finding that their intracellular activation modulates neuronal function. 12 Because CB 2 receptors have been found to signal through Ca 2+ , 12−15 we used calcium imaging and extracellular and intracellular administration of cannabinoid ligands to investigate the functionality of plasmalemmal versus intracellular CB 2 receptors in U2OS cells stably expressing CB 2 .
Zeocin, and 200 μg/mL G418 at 37°C in a humidified incubator with 5% CO 2 . The serum was removed 24 h prior to experimentation. In experiments that aimed to evaluate Gqdependent signaling, cell starvation was concomitant with incubation of D-[Trp7,9,10]-substance P (24 h).
Immunocytochemistry and Confocal Imaging Studies. U2OS cells transiently transfected with the GFP-tagged CB 2 receptor (kindly provided by M. Caron and L. S. Barak) and with Rab7-RFP (Addgene, Cambridge, MA) 48 h earlier were fixed with 4% paraformaldehyde, washed in phosphatebuffered saline, and mounted with DAPI Fluoromont G (Southern Biotech, Birmingham, AL). Cells were imaged using a Carl Zeiss 710 two-photon confocal microscope with a 63× oil immersion objective, using a 1× digital zoom, with excitations set for DAPI, GFP, and DsRed at 405, 488, and 561 nm, respectively. Images were analyzed using Zen 2010 (Zeiss), as previously reported. 16 Calcium Imaging. Measurements of [Ca 2+ ] i were performed as previously described. 16−19 Briefly, cells were incubated with 5 μM Fura-2 AM (Invitrogen) in HBSS at room temperature for 45 min, washed with dye-free HBSS, and incubated for an additional 45 min to allow dye deesterification. Coverslips were mounted in an open bath chamber (RP-40LP, Warner Instruments, Hamden, CT) on the stage of an inverted microscope (Nikon Eclipse TiE, Nikon Inc., Melville, NY), equipped with a Perfect Focus System and a Photometrics CoolSnap HQ2 CCD camera (Photometrics, Tucson, AZ). During the experiments, the Perfect Focus System was activated. Fura-2 AM fluorescence (emission at 510 nm), following alternate excitation at 340 and 380 nm, was acquired at a frequency of 0.25 Hz. Images were acquired and analyzed using NIS-Elements AR version 3.1 (Nikon Inc.). After appropriate calibration with ionomycin and CaCl 2 , and Ca
2+
-free and EGTA, respectively, the ratio of the fluorescence signals (340 nm to 380 nm) was converted to Ca 2+ concentration. 20 Intracellular Microinjection. Injections were performed using Femtotips II, InjectMan NI2, and FemtoJet systems (Eppendorf) as previously reported. 16−19 Pipettes were backfilled with an intracellular solution containing 110 mM KCl, 10 mM NaCl, and 20 mM HEPES (pH 7.2) or the compounds to be tested. The injection time was 0.4 s at 60 hectoPascal with a compensation pressure of 20 hectoPascal to ensure that the microinjected volume was <1% of the cell volume. The intracellular concentration of chemicals was determined on the basis of the concentration in the pipet and the volume of injection. The cells to be injected were Z-scanned before injection, and the cellular volume was automatically calculated by NIS-Elements AR version 3.1 (Nikon Inc.).
Statistics. Data are expressed as means and the standard error of the mean. One-way analysis of variance, followed by post hoc Bonferroni and Tukey tests, was used to assess significant differences between groups; P < 0.05 was considered statistically significant. ] i , by 7 ± 3.4 nM (n = 31 cells), 12 ± 5.1 nM (n = 43 cells), and 87 ± 3.1 nM (n = 56 cells), respectively ( Figure 1A ). The effect of the latter concentration of 2-AG was statistically significant (P < 0.05) and sensitive to CB 2 blockade with AM630 (1 μM, 10 min). In the presence of AM630, Δ[Ca
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] i was reduced to 14 ± 3.6 nM (n = 49) ( Figure 1A,B) . The effect of 2-AG on [Ca 2+ ] i was delayed by 1−2 min and increased gradually ( Figure 1B) .
In experiments using the intracellular microinjection technique, injection of 0.01, 0.1, and 1 μM 2-AG (final concentrations inside the cell) induced robust and significant increases in [Ca 2+ ] i of CB 2 -U2OS cells of 264 ± 11 nM (n = 6 cells), 653 ± 19 nM (n = 6 cells), and 938 ± 22 nM (n = 6 cells), respectively, while control buffer microinjection had an insignificant effect of 49 ± 4 nM (n = 6 cells) (Figure 2A−D) . In the presence of co-injected CB 2 antagonist AM630 (1 μM), 0.1 μM 2-AG elevated [Ca 2+ ] i by 58 ± 4 nM (n = 6 cells), similar to that of control buffer microinjection; the effect of 0.1 μM 2-AG on [Ca 2+ ] i of untransfected U2OS cells was also insignificant, measuring 34 ± 5 nM (n = 6 cells) ( Figure  2A ,B,E,F).
In all series of experiments using intracellular injection, CB 2 -U2OS cells were pretreated for 1 min with 1 μM AM630 (applied extracellularly), to exclude the possibility that the injected cannabinoid ligands leaked from the pipet and triggered plasma membrane receptor-mediated effects.
Functional and Morphological Evidence of Localization of CB 2 to Endolysosomes in CB 2 -Transfected U2OS Cells. CB 2 -U2OS cells were incubated for 1 h with either 1 μM bafilomycin A1, a V-type ATPase that prevents lysosomal acidification, 21 or 30 μM rapamycin, which blocks the last step of the engulfment of molecules by endolysosomes via microautophagy. 22 Under the conditions described above, the effect of 0.1 μM 2-AG on [Ca 2+ ] i , initially measuring 653 ± 19 nM, was drastically reduced to 36 ± 4.8 nM (n = 6 cells) and 67 ± 9.1 nM (n = 6 cells) ( Figure 3A−E) . In U2OS cells co-expressing GFP-tagged CB 2 receptors and RFP-tagged Rab7, a small GTPase associated with both endosomes and lysosomes, 23 we observed an extensive colocalization of CB 2 and Rab7 ( Figure 3F ). Lysosomal disruption using bafilomycin A1 greatly reduced the extent of the merged signal of CB 2 and Rab7 ( Figure 3F) . Figure 7A,B) ] similar to the effect of 2-AG on untreated cells. CTX irreversibly abolishes the GTPase activity of the Gs α subunit, inducing continual activation of adenylyl cyclase and increased intracellular levels of cAMP. In this manner, it hinders ligands of Gscoupled receptors from eliciting their Gs-dependent effects. After pretreatment with the Gi/o inhibitor pertussis toxin (PTX, 100 ng/mL), the response of 2-AG was negligibly modified, measuring 85 ± 4.2 nM [n = 53 cells ( Figure 7A,B) ]. Conversely, pretreatment of CB 2 -U2OS cells with Gq blocker D-[Trp7,9,10]-substance P (D-SP, 100 ng/mL) 24 greatly reduced the effect of 2-AG to 7 ± 2.7 nM [n = 67 cells ( Figure 7A,B) ].
The Ca 2+ response elicited by anandamide was largely similar and not significant regardless of whether anandamide was ] i values were 257 ± 6.8 nM (n = 53 cells) and 243 ± 7.9 nM (n = 47 cells) in cells pretreated with CTX and PTX, respectively, and 262 ± 6.8 nM (n = 49 cells) for WIN55,212-2 alone (Figure 7A,B) .
Intracellular CB 2 Receptors Couple to Gq Proteins. Overnight treatment of CB 2 -U2OS cells with CTX (100 ng/ mL) or PTX (100 ng/mL) failed to significantly modify the Ca 2+ response elicited by intracellular administration of 0.1 μM 2-AG ( Figure 8A,B) . Under the conditions described above, 2-AG increased [Ca 2+ ] i by 654 ± 21 nM (n = 6 cells) and 629 ± 18 nM (n = 6 cells), respectively, while the response to 2-AG alone measured 652 ± 19 nM [n = 6 cells ( Figure 8A,B) ]. After incubation of cells with D-SP (100 ng/mL), the effect of 2-AG was greatly decreased to 62 ± 23 nM (n = 6 cells), indicating participation of a Gq-dependent pathway in the response ( Figure 8A,B) . ] i values were 668 ± 13 nM (n = 6 cells) and 641 ± 9.8 nM (n = 6 cells) after CTX and after PTX, respectively, and 635 ± 7.1 nM for WIN55,212-2 alone. However, blocking Gq proteins with 100 ng/mL D-SP basically abolished the effect of intracellular WIN55,212-2. In this case, Δ[Ca
] i decreased to 27 ± 5.4 nM [n = 6 cells ( Figure 8A,B) ].
Activation of Intracellular CB 2 Mobilizes Ca 2+ from Distinct Pools. CB 2 -U2OS cells incubated with Ca (Figure 2) ], indicating mobilization of both intracellular and extracellular Ca 2+ pools. Using a pharmacological approach, we further sought to identify the intracellular sources of Ca 2+ involved in the response to microinjected 2-AG. Pretreatment of cells with ryanodine receptor blocker ryanodine (10 μM, 1 h) did not significantly modify the Ca 2+ response to 2-AG, which measured 452 ± 5.9 nM [n = 6 cells ( Figure 9A,B) ]. Conversely, pretreatment with Ned-19 (5 μM, 15 min), which blocks endolysosomal Ca 2+ release via the NAADP-sensitive two-pore channels, 25 decreased the extent of 
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In addition to the effects initiated at the plasma membrane, G protein-coupled receptors (GPCRs) may also trigger signaling cascades upon their activation within the cell. 26 The emerging paradigm of functional intracellular GPCRs is particularly significant in the case of lipid messengers that are generated intracellularly and may target their receptors at both sites, (reviewed in ref 27). We and others reported the functionality of intracellularly expressed CB 1 ] i increase may occur downstream of Gi, 32, 33 we noticed that the CB 2 -dependent effects of 2-AG or WIN55,212-2 were completely contingent on Gq in our paradigm. WIN55,212-2 also activates Gq downstream of CB 1 ; 31 moreover, it can trigger a CB 2 -dependent signaling pathway different from that elicited by other ligands. 7 Thus, the discrepancy between the effects of extracellular administration of anandamide, 2-AG, and WIN55,212-2 in our study may be a result of the reported functional selectivity at CB 2 receptors. 7, 34 In a recent study, we demonstrated that anandamide can trigger fast CB 1 -dependent Ca 2+ signaling upon microinjection but is ineffective upon extracellular administration in CB 1 -transfected cells. 17 To test the hypothesis of functional intracellular CB 2 receptors in CB 2 -U2OS cells, intracellular injections of 2-AG, anandamide, or WIN55,212-2 were conducted. When 2-AG or anandamide was microinjected, concentration-dependent elevations of [Ca 2+ ] i were observed, and the Ca 2+ response pattern was very fast, which is in contrast with the delayed, modest response and lack of effect, respectively, observed with the extracellular administration of these two agonists. Likewise, intracellular administration of WIN55,212-2 resulted in a concentration-dependent and robust effect. WIN55,212-2 and 2-AG produced Ca 2+ responses with an amplitude higher than that of anandamide, which is consistent with the full agonistic activity at CB 2 receptors reported for these ligands. 1, 29 The sensitivity of these responses to the intracellular blockade of CB 2 and the unresponsiveness of control, untransfected U2OS cells to microinjected cannabinoids were considered to be indicative of CB 2 specificity. We further noticed that interfering with Gqdependent, but not with Gs-or Gi/o-dependent, signaling prevented the effect of microinjected 2-AG, anandamide, or WIN55,212-2. Moreover, the endocannabinoids and WIN55,212-2 trigger similar signaling pathways upon intracellular administration, despite their unrelated chemical structure.
The accumulating evidence pointing to endolysosomes as intracellular locations where GPCRs initiate signaling 16, 18, 19, 35, 36 prompted us to evaluate whether this may be the case for CB 2 . In an initial functional study, we found that the effect of intracellular 2-AG is abolished by lysosomal disruption. Because rapamycin reduced the effects of microinjected 2-AG, ligand microautophagy 22 may be a necessary step in the activation of endolysosomally located CB 2 . The localization of CB 2 to lysosomes was confirmed by an additional study, providing morphological evidence that CB 2 colocalizes with the endolysosomal-associated small GTPase Rab7. Lysosomal disruption with bafilomycin A1 markedly reduced the fluorescence intensity of both CB 2 and Rab7, supporting the findings of the functional study.
Next, we sought to examine the pools of Ca 2+ mobilized upon activation of intracellularly located CB 2 . The reduction in the amplitude of the Ca 2+ response of CB 2 -U2OS cells incubated with Ca 2+ -free saline to microinjected 2-AG indicated that both influx of extracellular Ca 2+ and release of Ca 2+ from intracellular stores occur downstream of intracellular CB 2 activation. Using a pharmacological approach, we further determined that 2-AG-induced stimulation of intracellular CB 2 results in Ca 2+ mobilization from endolysosomes via NAADP-sensitive two-pore channels and from the endoplasmic reticulum via the IP 3 R. This effect correlates well with the localization of CB 2 at the endolysosmes, as well as with the localization of NAADP-generating enzymes 37, 38 at the membrane of acidic organelles. Thus, we conclude that intracellular CB 2 receptors are functional, endolysosomally located, and Gq-coupled in CB 2 -U2OS cells, and their activation mobilizes NAADP-sensitive acidic-like Ca 2+ stores and inositol 1,4,5-trisphosphate-sensitive endoplasmic reticulum pools. In addition, we note that CB 2 agonists elicit discrepant and delayed effects and exhibit a considerably lower potency when administered extracellularly as opposed to intracellularly. Although these effects appear to be Gq-mediated, it may be that a considerable pool of plasmalemmal CB 2 receptors do not couple with Gq/Ca 2+ signaling. Conversely, Gq coupling and associated Ca 2+ responses may be a characteristic of intracellularly located CB 2 , in which case the delay in the effects elicited by agonists upon extracellular administration may be a result of the latency necessary for membrane permeation. Nonetheless, differential activation of plasmalemmal CB 2 by the three agonists (applied extracellularly) is more likely to be a result of the functional selectivity at CB 2 , 7, 34 which is supported by the previous finding that 2-AG (which promotes agonist-directed trafficking at CB 2 34 ) has a low potency at eliciting CB 2 -mediated Ca 2+ responses. 34 Binding of a particular agonist to a GPCR results in the enrichment of a unique set of receptor conformations based on the microaffinity of the agonist for each conformation; because distinct conformations presumably couple receptors differently to specific G proteins and intracellular effectors, individual agonists ultimately produce distinct effects. 11 As such, anandamide, 2-AG, and WIN55,212-2 may induce conformational changes in plasmalemmal CB 2 , resulting in distinct responses, as observed in the study presented here. However, we note that this is not the case with intracellular, endolysosomally located CB 2 , which appears to couple to the same Gq-mediated Ca 2+ pathway in response to intracellular administration of the three agonists; moreover, the three agonists have higher potency and efficacy at eliciting intracellularly initiated CB 2 -dependent Ca 2+ responses. Thus, functional selectivity may apply more to plasmalemmal than to intracellular CB 2 .
On a different note, plasma membrane-located CB 2 is internalized upon agonist stimulation and slowly recycled back to the cell surface via a Rab11-dependent pathway, while rapid recycling, via Rab4, does not occur. 40 Moreover, in the case of CB 2 , not all receptors are recycled, and chronic agonist stimulation does not promote switching from recycling to degradative pathways, supporting the hypothesis of a putative role of sequestration of the CB 2 receptor to the cytoplasm following internalization. 40 Our results, together with those of others, 12 add further complexity to the CB 2 receptor pharmacology and argue for careful consideration of receptor localization in the development of CB 2 -based therapeutic agents. Moreover, because 2-AG is intracellularly produced "on demand", 41 its first target may be intracellularly located CB 2 , which may be relevant both in physiological states and in pathologies with an increased level of production of endocannabinoids.
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